SABCS 2022 Meeting News Welcome Edition - 8

8
PRESENTER
PROFILE:
Chiaojung Jillian
Tsai, MD, PhD
Radiation Oncologist
Memorial Sloan
Kettering Cancer
Center, New York, NY
EDUCATIONAL SESSION:
State of the Art Radiotherapy:
Reducing Toxicity and
Increasing Options
Friday, 3:00 pm - 5:00 pm CT
Stars at Night Ballroom 3&4
PRESENTATION:
Evidence for ablative radiation
in metastatic breast cancer
Q: What is your presentation about?
A: I'll be discussing the current evidence and challenges in using
ablative radiation in patients with metastatic breast cancer, as well as
practical aspects in incorporating radiotherapy in metastatic breast
cancer management.
Q: What makes this topic important in 2022?
A: More and more patients with metastatic breast cancer are living
longer because of advancement in treatment and diagnosis. There are
a large number of patients living with metastatic breast cancer, and it is
important to continue finding ways to improve both patient survival and
quality of life after treatment.
Q: How/why did you become involved with this area of
breast cancer research or care?
A: I specialize in using radiation to treat patients with metastatic cancer
to improve their quality of life and survival outcomes. My life has been
touched by many meaningful interactions with my metastatic breast
cancer patients that propelled me to do better in finding a better therapy
option for them. 
FRIDAY & SATURDAY, DECEMBER 9-10
SCHEDULE-AT-A-GLANCE
*As of November 18, 2022 | **All times are CENTRAL Time
FRIDAY, DECEMBER 9
7:00 am - 8:15 am CT
8:30 am - 9:00 am CT
POSTER SESSION #6
Hall 1
SPOTLIGHT POSTER
DISCUSSION SESSION
#16:
Imaging to Diagnose
Breast Cancer and Direct
Its Treatment: Who,
When, and How?
Hemisfair Ballroom
SPOTLIGHT POSTER
DISCUSSION SESSION
#17
Endocrine Therapy New
Insights
Stars at Night Ballroom
1&2
SPOTLIGHT POSTER
DISCUSSION SESSION
#18
Updates and New
Therapies for HER2
Positive Disease
Stars at Night Ballroom
3&4
AACR Outstanding
Investigator Award for
Breast Cancer Research
Hall 3
9:00 am - 11:30 am CT
GENERAL SESSION #4
Hall 3
10:00 am - 5:00 pm CT
EXHIBITS
Hall 2
11:30 am - 12:00 pm CT
Brinker Award for Scientific
Distinction in
Clinical Research
Norman Wolmark, MD,
FACS, FRCSC
Hall 3
12:00 pm - 3:00 pm CT
GENERAL SESSION #5
Hall 3
3:00 pm - 5:00 pm CT
EDUCATIONAL SESSION
BLOCK #4
Advances in Pregnancy
Associated Breast
Cancer (PABC)
Stars at Night Ballroom 1&2
ABSTRACT PRESENTATIONS
Friday, December 9 | 9:00 am - 11:30 am CT | Hall 3
GENERAL SESSION #4
9:00 am - 9:15 am CT
GS4-01: Impact of
breast conservation
therapy on local
recurrence in patients
with multiple ipsilateral
breast cancer - Results
from ACOSOG Z11102
(Alliance)
9:15 am - 9:30 am CT
GS4-02: Oncological
outcomes following
omission of axillary
lymph node dissection
in node positive
patients downstaging
to node negative
with neoadjuvant
chemotherapy:
the OPBC-04/
EUBREAST-06/OMA
study
9:30 am - 9:45 am CT
GS4-03 Validation
of Profile for
the Omission of
Local Adjuvant
Radiotherapy
(POLAR) in a
meta-analysis of
three randomized
controlled trials of
breast conserving
surgery +/radiotherapy
9:45
am - 10:00 am CT
GS4-04: Populationbased
estimates of
contralateral breast
cancer risk among
carriers of germline
pathogenic variants in
ATM, BRCA1, BRCA2,
CHEK2, and PALB2
10:00 am - 10:15 am CT
GS4-05: Phase II
randomized trial of
conventional versus
hypofractionated postmastectomy
proton
radiotherapy
10:15 am - 10:30 am CT
GS4-06: Radiomic
phenotypes of
breast texture and
association with
breast cancer risk and
masking
10:30 am - 10:45 am CT
Discussant for GS4-06
10:45 am - 11:00 am CT
GS4-08: 10-year
results of a phase
3 trial of low-dose
tamoxifen in non-
invasive breast cancer
11:00 am - 11:15 am CT
GS4-09: Pregnancy
Outcome and Safety of
Interrupting Therapy
for women with
endocrine responsIVE
breast cancer: Primary
Results from the
POSITIVE Trial (IBCSG
48-14 / BIG 8-13)
11:15 am - 11:30 am CT
Discussant for GS4-09
State of the Art
Radiotherapy: Reducing
Toxicity and Increasing
Options
Stars at Night Ballroom
3&4
Targeting the Tumor
Microenvironment for
Clinical Impact
Hemisfair Ballroom 1&2
5:00 pm - 5:15 pm CT
Refreshment Break
5:15 pm - 7:15 pm CT
View from the Trenches:
What will You do on
Monday Morning?
Stars at Night Ballroom
1&2
SATURDAY,
DECEMBER 10
8:00 am - 10:00 am CT
The Year In Review
Hall 3
10:00 am CT
Meeting Adjourns
GENERAL SESSION #5
Friday, December 9 | 12:00 pm - 3:00 pm CT | Hall 3
12:00 pm - 12:15 pm CT
GS5-01: Addition of platinum
to sequential taxane-
anthracycline neoadjuvant
chemotherapy in patients
with triple-negative
breast cancer: A phase III
randomized controlled trial
12:15 pm - 12:30 pm CT
GS5-02: GeparOLA trial:
paclitaxel + olaparib combination
in HER2 negative
and high HRD score - longer
term survival follow up
12:30 pm - 12:45 pm CT
GS5-03: Evaluation of
anti-PD-1 Cemiplimab plus
anti-LAG-3 REGN3767
in early-stage, high-risk
HER2-negative breast
cancer: Results from the
neoadjuvant I-SPY 2 TRIAL
12:45 pm - 1:00 pm CT
GS5-04: Identification
of symptoms that are
associated with irAEs in the
I-SPY clinical trial
1:00 pm - 1:15 pm CT
GS5-05: ZNF689 deficiency
promotes intratumor
heterogeneity and resistance
to immune checkpoint
blockade in triple-negative
breast cancer
1:15 pm - 1:30 pm CT
GS5-06: InteractPrint
predicts clinically
meaningful interactions
between cancer epithelial
cells and immune cells:
Lessons from a single-cell
breast cancer atlas
1:30 pm - 1:45 pm CT
GS5-07: Estradiol represses
anti-tumoral immune
response to promote
progression of triplenegative
breast cancer brain
metastases
1:45 pm - 2:00 pm CT
GS5-08 Soluble E-cadherin:
a novel prognostic
biomarker and driver of brain
metastasis in inflammatory
breast cancer
WELCOME EDITION | SABCSMEETINGNEWS . ORG
2:00 pm - 2:15 pm CT
Discussant for GS5-07 and
GS5-08
2:15 pm - 2:30 pm CT
GS5-10: Utility of the 70gene
MammaPrint test
for prediction of extended
endocrine therapy benefit
in patients with early-stage
breast cancer in the IDEAL
Trial
2:30 pm - 2:45 pm CT
GS5-11: Second interim
analysis of overall survival
(OS) from the TROPiCS-02
phase 3 study of
sacituzumab govitecan (SG)
vs treatment of physician's
choice (TPC) in patients
with HR+/HER2- advanced
breast cancer
2:45 pm - 3:00 pm CT
GS5-12: Hypofractionated
Radiotherapy in patients
with Breast Cancer (HRBC):
Acute toxicity data of a
phase III randomized study
SABCS 2022 Meeting News Welcome Edition

Table of Contents for the Digital Edition of SABCS 2022 Meeting News Welcome Edition
